Oxford BioMedica plc (LON:OXB) had its target price increased by equities researchers at N+1 Singer from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) in a report released on Thursday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. N+1 Singer’s price target points to a potential upside of 1.16% from the stock’s previous close.

A number of other brokerages also recently commented on OXB. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 13 ($0.17) target price on shares of Oxford BioMedica plc in a report on Thursday, July 13th. Shore Capital restated a “not rated” rating on shares of Oxford BioMedica plc in a report on Thursday, July 13th.

Shares of Oxford BioMedica plc (OXB) traded down 1.05% during midday trading on Thursday, hitting GBX 8.51. 449,513 shares of the stock were exchanged. Oxford BioMedica plc has a 1-year low of GBX 2.98 and a 1-year high of GBX 11.25. The firm has a 50-day moving average of GBX 7.40 and a 200-day moving average of GBX 5.30. The company’s market capitalization is GBX 262.45 million.

TRADEMARK VIOLATION WARNING: This article was published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/27/oxford-biomedica-plc-lonoxb-given-new-gbx-8-70-price-target-at-n1-singer.html.

In other news, insider Lorenzo Tallarigo bought 49,033 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The shares were purchased at an average price of GBX 5 ($0.07) per share, for a total transaction of £2,451.65 ($3,193.92). Also, insider Martin Diggle bought 660,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was purchased at an average price of GBX 9 ($0.12) per share, for a total transaction of £59,400 ($77,384.05). In the last 90 days, insiders have bought 1,011,980 shares of company stock worth $8,448,961.

Oxford BioMedica plc Company Profile

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.